The Gut–Vagus–Brain Loop: Microbiome, Inflammation, and Mood Regulation

Learning outcome: Trace several gut–brain communication routes and recognise the limits of translating mechanisms into treatment claims.

Several routes, working together

Gut–brain communication includes vagal and spinal sensory pathways, enteric circuits, hormones, immune signalling and circulating metabolites. The vagus is one important route; it is not a cable carrying bacteria or neurotransmitters directly into the brain.

Sensory endings detect mechanical conditions such as distension and receive information related to nutrients and chemical signals. Some signals reach nerve endings through epithelial or enteroendocrine cells. Brainstem circuits coordinate reflex responses and relay information to wider networks. The cellular diversity described by Prescott and Liberles helps explain why “more vagal activity” is too vague to specify an effect.

Serotonin: location matters

Much of the body’s serotonin is produced in the gut, where it has local and peripheral functions. This does not mean that gut serotonin simply crosses into the brain to raise brain serotonin. A plausible peripheral signalling pathway and an antidepressant effect are separate claims.

Microbial metabolites, immune mediators and changes in gut function can influence signalling. Findings from animal experiments, including vagotomy studies, help test pathways but do not establish that a probiotic or an IEMT session treats depression through the vagus in humans.

The inflammatory reflex

Neuroimmune communication includes sensory detection of inflammatory signals and neural regulation of immune responses. The cholinergic anti-inflammatory pathway involves multi-step signalling, including immune-cell acetylcholine and receptor pathways in experimental models. It should not be simplified into a claim that the vagus directly innervates every immune cell or that relaxation suppresses all inflammation.

Pavlov and Tracey’s review provides a mechanistic foundation. Later clinical evidence must be considered separately. For example, the FDA approved a specific implanted SetPoint system for a defined rheumatoid arthritis population in July 2025. That indication is not evidence for consumer devices, humming or general treatment of inflammatory illness. See the original approval record.

From association to clinical application

Ask whether a study is in cells, animals, healthy volunteers or patients. Check the exact intervention, comparison, outcome and duration. A change in a cytokine is not automatically a meaningful improvement in pain, fatigue or daily function. A microbiome association may reflect diet, medication, illness or other confounders.

Support appropriate assessment of persistent digestive symptoms. Do not diagnose “dysbiosis”, impaired vagal tone or a leaky gut from mood, fatigue or a commercial microbiome report alone. Dietary and medical treatment should follow the person’s diagnosis and the relevant professional expertise.

Medical reading and sources

• Prescott & Liberles (2022). Internal senses of the vagus nerve.
• Breit et al. (2018). Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders.
• Pavlov & Tracey (2012). The vagus nerve and the inflammatory reflex: linking immunity and metabolism.
• FDA (30 July 2025). SetPoint System approval, P240039.

Illustrations and further viewing

The original course media are retained below. Diagrams of emotional states illustrate a proposed model; they do not measure nerve activity. Read any claims in external videos alongside the evidence and limitations above.

Return to the course index, reading library and assessment

Teaching text revised 13 October 2026. This lesson supports professional learning; it does not confer competence to diagnose disease or prescribe stimulation.